Viracta Therapeutics (NASDAQ:VIRX) Given “Buy” Rating at HC Wainwright

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 324.40% from the stock’s previous close.

Viracta Therapeutics Price Performance

Shares of NASDAQ VIRX opened at $0.94 on Tuesday. The business’s 50 day moving average is $0.90 and its two-hundred day moving average is $0.70. Viracta Therapeutics has a 1-year low of $0.43 and a 1-year high of $2.38. The stock has a market capitalization of $37.01 million, a P/E ratio of -0.71 and a beta of 0.93.

Viracta Therapeutics (NASDAQ:VIRX) last released its earnings results on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). As a group, equities research analysts anticipate that Viracta Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Viracta Therapeutics by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 1,161,280 shares of the company’s stock valued at $662,000 after buying an additional 13,368 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Viracta Therapeutics by 22.2% in the third quarter. BlackRock Inc. now owns 662,600 shares of the company’s stock valued at $2,830,000 after purchasing an additional 120,169 shares during the period. State Street Corp boosted its holdings in shares of Viracta Therapeutics by 2.3% in the first quarter. State Street Corp now owns 588,603 shares of the company’s stock valued at $2,802,000 after purchasing an additional 13,514 shares during the period. Millennium Management LLC purchased a new stake in shares of Viracta Therapeutics in the second quarter valued at approximately $1,227,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Viracta Therapeutics by 3.0% in the fourth quarter. Geode Capital Management LLC now owns 224,438 shares of the company’s stock valued at $327,000 after purchasing an additional 6,502 shares during the period. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.